



Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



January 15, 1996
Volume 56 • Number 2
PP. 235-427
ISSN 0008-5472 • CNREA 8



DAKO

Your quality source for antibodies

■ Apoptosis & Cell Cycle

bcl-2 oncoprotein*, clone: 124

p53 protein*, clone: DO-7

CD16 Fc γ receptor III, clone: DJ130c*[†],
clone: VIFcRIII

Ki-67 antigen, polyclonal

Ki-67 antigen, monoclonal*[†], clone: Ki-67

mitotic proteins, clone: MPM-2

proliferating cell nuclear antigen
(PCNA)*[†], clone: PC10

CD71, transferrin receptor*,
clone: Ber-T9

bromodeoxyuridine, clone: Bu20a

terminal deoxynucleotidyl transferase
(TdT), clone: HT-1/3/4

■ Cell Adhesion Molecules & Integrins

CD11a LFA-1, α chains*, clone: MHM24

CD11b C3bi receptor[†], clone: 2LPM19c

CD11c protein 150, 95*, clone: KB90

CD18 LFA-1, β chains*, clone: MHM23

CD29 T-cell, integrin β 1*, clone: K20

CD49b integrin α 2 β 1, clone: P1E6

CD49c integrin α 3 β 1, clone: P1B5

CD49d integrin α 4 β 1, clone: P4G9

CD49e integrin α 5 β 1, clone: P1D6

CD50 ICAM-3, clone: KS128

CD54 ICAM-1, clone: 6.5B5

CD61 platelet glycoprotein IIIa,
integrin β 3*, clone: Y2/51

N-CAM clone: UJ12A

* Also available conjugated to FITC

[†] Also available conjugated to R-phycoerythrin


FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Call us for other cell biology antibodies in our extensive line.

DAKO Corporation is a leading worldwide manufacturer of monoclonal and polyclonal antibodies, visualization systems, *In situ* hybridization, flow cytometry and microbiology products.

TECHNICAL SUPPORT: 800/424-0021 ■ TO PLACE AN ORDER: 800/235-5763

COVER LEGEND



The General Motors Cancer Research Foundation was founded in 1978 by Roger B. Smith, then Chief Executive Officer and Chairman of the Board of General Motors. The success of the Foundation in recognizing the contributions of scientists and clinicians to the cure of cancer has rested firmly on the shoulders of two individuals: Jonathan E. Rhoads (*right*), Chairman of the Awards Assembly, and Joseph G. Fortner (*center*), President of the Foundation, who together set up a rigorous process by which to choose who most deserved the annual prizes for scientific contributions to the cure of cancer. In 1995, Phillip A. Sharp (*left*) took over the Awards Assembly Chairmanship upon Dr. Rhoads' retirement.

Dr. Rhoads brought to the Foundation a wealth of experience and wisdom, through which he has long contributed to the battle against cancer. He earned his M.D. from Johns Hopkins in 1932, and through a long and distinguished academic career at the University of Pennsylvania, he has contributed to all aspects of the cancer field: empathetic patient care, surgical research (surgical nutrition with the development of intravenous hyperalimentation), administrative (Professor and Chairman of the Department of Surgery) and scholastic (Provost of the University) leadership, editorial leadership in surgery and cancer, and national leadership (development of the National Cancer Act in 1971, Chairmanship of the National Cancer Advisory Board from 1972 to 1979, and trusteeship in the General Motors Foundation). His wisdom has been dispersed over 380 original publications.

Dr. Fortner has been Foundation President since its inception. He received his M.D. from the University of Illinois College of Medicine in 1954. At Memorial Hospital and Cornell University Medical College in New York, he has contributed as trainee, surgeon, cancer researcher (focusing on liver cancer and innovations in liver transplantation), and capable administrator. Dr. Fortner administers the Foundation, inspiring, cajoling, and recruiting leaders in cancer research from

around the world to form Selection Committees, the Awards Assembly, and the Advisory Council to most appropriately award three annual prizes, each consisting of a gold medal and \$100,000. The Kettering Prize is given for the most outstanding advance in the diagnosis or treatment of cancer. It is named for Charles F. Kettering, former Director of General Motors. The Mott Prize, named for Charles S. Mott, a General Motors philanthropist, is given for the most important contribution to understanding the cause and prevention of cancer. The Sloan Prize is given for significant basic research clarifying the underlying nature of cancer, and is named for Alfred P. Sloan, Jr., an early pioneer at General Motors. Since 1978, 41 scientists from around the world have been honored. The countries they have emanated from include the United States, Great Britain, Israel, Australia, Germany, Sweden, Japan, and Canada.

The Foundation has reached a turning point as Dr. Sharp takes over the Chairmanship of the Awards Assembly. Dr. Sharp shared the 1993 Nobel Prize in Physiology and Medicine with Richard A. Roberts for their discovery of introns. He received his Ph.D. in Chemistry from the University of Illinois in 1969, carried out postdoctoral work at Cold Spring Harbor Laboratory, and then joined the MIT Center for Research. He is a recipient of many awards, including the Sloan Prize of the Foundation. Dr. Sharp brings to the Awards Assembly an intellectual prowess, characterized by a profound understanding of the problems of cancer and molecular biology, at a time when the molecular understanding of cancer is moving from the esoteric to the practical. There is no doubt that he will serve society, cancer scientists, and the Foundation admirably. However, Jonathan Rhoads will be profoundly missed, especially for his ability to clarify and simplify the issues of a hot debate effectively with a direct, humorous, and to-the-point story.

Drs. Rhoads, Fortner, and Sharp are active members of the American Association for Cancer Research (AACR), all of them having contributed greatly of their time and talents to the Association. Each has served on key AACR Committees. Dr. Fortner held two consecutive terms on the Finance Committee, the second one ending in 1995. Dr. Rhoads has also been a member of the Finance Committee, and he chaired the first standing Development Committee beginning in 1988, thus spearheading the essential fund-raising activities of the Association. Other committees he has served on include the Long-Range Planning and the Special (Sustaining) Membership Committees. Dr. Sharp is currently on the Special Conferences Committee, which shapes the very important series of small conferences that the AACR holds throughout the year. He organized the first of these conferences, which was supported by the Foundation, in 1988. He is also a member of the International Affairs Committee and has served on the G. H. A. Clowes and the Cornelius P. Rhoads Awards Committees, acting as Chairperson for the latter in 1994-95.

We thank Dr. Fortner for providing the photograph for this cover feature.

Brenda Gallie